Subtype
Prostate Neoplasm
CI-CAN-00003778Explore in graph →
Non-malignant1,453 active trials24 approved drugs58 evidence items
Loading cancer entity…
Loading cancer entity…
Subtype
CI-CAN-00003778Explore in graph →
Clinical trials
6,544 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT05807126 | Testing the Addition of Immunotherapy With Hu5F9-G4 (Magrolimab) to the Usual PARP Inhibitor, Olaparib for Treatment of Metastatic or Recurrent Breast or Castrate-Resistant Prostate Cancer With BRCA Mutations | withdrawn | Phase 1 | 0 | National Cancer Institute (NCI)NIH | 1 | May 2, 2024 | clinicaltrials |
| NCT05445882 | N-803 Alone or in Combination With BN-Brachyury Vaccine or Bintrafusp Alfa (M7824) for Participants With Castration Resistant Prostate Cancer | withdrawn | Phase 2 | 0 | National Cancer Institute (NCI)NIH | 1 |
| Apr 2, 2024 |
| clinicaltrials |
| NCT04243941 | PSMA-PET/MRI Low- and Intermediate-Risk Prostate Cancer | withdrawn | Phase 2 | 0 | UNC Lineberger Comprehensive Cancer CenterOTHER | 0 | Mar 21, 2024 | clinicaltrials |
| NCT03909893 | A Study of Adaptive Radiation Therapy for Pelvic Genitourinary Cancer(ARTGU) | withdrawn | N/A | 0 | University Health Network, TorontoOTHER | 1 | Mar 19, 2024 | clinicaltrials |
| NCT05574712 | A Neoadjuvant Study of Abiraterone Acetate, Leuprolide Acetate, and Belzutifan in Men With Regional Prostate Cancer | withdrawn | Phase 2 | 0 | Sidney Kimmel Comprehensive Cancer Center at Johns HopkinsOTHER | 0 | Mar 18, 2024 | clinicaltrials |
| NCT05034562 | Gallium-68 PSMA-11 PET in Participants With Prostate Cancer | withdrawn | Phase 2 | 0 | M.D. Anderson Cancer CenterOTHER | 0 | Mar 7, 2024 | clinicaltrials |
| NCT05156372 | Adjuvant High-intensity Interval Training During Chemotherapy in Metastatic Prostate Cancer Patients(HIIT PCa) | withdrawn | N/A | 0 | The University of Texas Health Science Center at San AntonioOTHER | 1 | Feb 26, 2024 | clinicaltrials |
| NCT03970863 | Focal Therapy for Localized Prostate Cancer | withdrawn | — | 0 | China Medical University HospitalOTHER | 1 | Feb 9, 2024 | clinicaltrials |
| NCT04304079 | A Novel Augmented Reality System (ARssist) for the Assistant Surgeon in Robotic Assisted Surgery | withdrawn | N/A | 0 | Chinese University of Hong KongOTHER | 1 | Jan 23, 2024 | clinicaltrials |
| NCT05238831 | SMMART Adaptive Clinical Treatment (ACT) Trial | withdrawn | Early Phase 1 | 0 | OHSU Knight Cancer InstituteOTHER | 0 | Jan 23, 2024 | clinicaltrials |
| NCT05035732 | A Prospective Pilot Study for the Evaluation of 18F- Fluciclovine PET/MRI in Radio-recurrent Prostate Cancer (RRPC-PET/MRI Study) | withdrawn | N/A | 0 | M.D. Anderson Cancer CenterOTHER | 0 | Jan 18, 2024 | clinicaltrials |
| NCT00323180 | Investigation of Protein Biomarkers of Prostate Cancer | withdrawn | — | 0 | University of New MexicoOTHER | 1 | Jan 11, 2024 | clinicaltrials |
| NCT00323388 | Identification of Risk Allels for Prostate Cancer | withdrawn | — | 0 | University of New MexicoOTHER | 1 | Jan 11, 2024 | clinicaltrials |
| NCT03494803 | Detection of Prostate Cancer With Non-invasive Method Based on DNA Methylation of Circulated Tumor DNA, PBMC | withdrawn | — | 0 | HKGepitherapeuticsINDUSTRY | 1 | Dec 22, 2023 | clinicaltrials |
| NCT03338712 | Micro-RNA Expression Profiles in Localised Prostate Cancer | withdrawn | — | 0 | Wuerzburg University HospitalOTHER | 0 | Dec 12, 2023 | clinicaltrials |
| NCT06159998 | New Markers for Treatment Response to Radiotherapy in Prostate Cancer | withdrawn | — | 0 | University of BaselOTHER | 1 | Dec 7, 2023 | clinicaltrials |
| NCT05454371 | Investigation of Urinary Biomarkers for the Detection of Prostate Cancer(URODETECT-WP2) | withdrawn | N/A | 0 | Novosanis NVINDUSTRY | 1 | Nov 13, 2023 | clinicaltrials |
| NCT05567679 | A Study of Tazemetostat (Tazverik) Before Prostatectomy in Men With Prostate Cancer | withdrawn | Early Phase 1 | 0 | Edwin Posadas, MDOTHER | 1 | Sep 22, 2023 | clinicaltrials |
| NCT05771896 | Darolutamide With Radium-223 or Placebo and the Effect on Radiological Progression-Free Survival for Patients With mCSPC(CARE) | withdrawn | Phase 3 | 0 | GenesisCare USAOTHER | 0 | Sep 14, 2023 | clinicaltrials |
| NCT05098327 | Pioglitazone and Insulin Resistance in ADT | withdrawn | Phase 3 | 0 | State University of New York at BuffaloOTHER | 1 | Aug 15, 2023 | clinicaltrials |
| NCT01555632 | Atorvastatin Calcium in Preventing Metabolic Syndrome in Prostate Cancer Patients Receiving Androgen-Deprivation Therapy | withdrawn | N/A | 0 | University of NebraskaOTHER | 0 | Aug 14, 2023 | clinicaltrials |
| NCT04781374 | Neratinib in Patients With Metastatic Castration-Resistant Prostate Cancer | withdrawn | Phase 2 | 0 | Beth Israel Deaconess Medical CenterOTHER | 1 | Jul 11, 2023 | clinicaltrials |
| NCT05363644 | BioDFence® G3 For Full Nerve-Sparing Robotic-Assisted Radical Prostatectomy | withdrawn | Phase 3 | 0 | AdventHealthOTHER | 1 | Jun 29, 2023 | clinicaltrials |
| NCT04995978 | Insulin Resistance and Androgen Deprivation Therapy | withdrawn | Phase 2 | 0 | St. Louis UniversityOTHER | 1 | Jun 23, 2023 | clinicaltrials |
| NCT05742334 | Evaluating Return to Continence and Potency Following Radical Prostatectomy | withdrawn | N/A | 0 | Wake Forest University Health SciencesOTHER | 0 | Jun 2, 2023 | clinicaltrials |
| NCT00771017 | Androgen Ablation Therapy With or Without Vaccine Therapy in Treating Patients With Prostate Cancer | withdrawn | Phase 2 | 0 | Eastern Cooperative Oncology GroupNETWORK | 0 | May 25, 2023 | clinicaltrials |
| NCT04483414 | 68Ga PSMA-11 PET/CT in Recurrent Prostate Cancer | withdrawn | Phase 2 | 0 | Dana MathewsOTHER | 1 | May 19, 2023 | clinicaltrials |
| NCT04658849 | Insulin Resistance Following ADT for Prostate CA | withdrawn | Early Phase 1 | 0 | St. Louis UniversityOTHER | 1 | May 15, 2023 | clinicaltrials |
| NCT04879589 | Phase 1 Study of ATRS-2002 in Healthy Male Adults | withdrawn | Phase 1 | 0 | Syneos HealthOTHER | 0 | Apr 28, 2023 | clinicaltrials |
| NCT05245435 | Diagnostic and Prognostic Accuracy of FDHT-PET and Liquid Biopsies in Prostate Cancer | withdrawn | N/A | 0 | Medical University of ViennaOTHER | 1 | Mar 20, 2023 | clinicaltrials |
| NCT03122470 | Correlation of Imaging Findings With Clinical Findings and Patient Outcomes in Prostate Cancer | withdrawn | N/A | 0 | Case Comprehensive Cancer CenterOTHER | 0 | Mar 16, 2023 | clinicaltrials |
| NCT04797078 | US/MRI Fusion Local Anestesia TransPerineal Prostate Biopsies for Detection of Prostate Cancer(FLAPP) | withdrawn | N/A | 0 | Karolinska InstitutetOTHER | 0 | Mar 10, 2023 | clinicaltrials |
| NCT01792882 | Prospective Collection of Surplus Surgical Tumor Tissues and Pre-surgical Blood Samples(GBCPRT0008) | withdrawn | — | 0 | Global BioClinicalINDUSTRY | 1 | Feb 28, 2023 | clinicaltrials |
| NCT05705700 | Biomarker Study of in Men With PSA Progression on Abi for CR or CS PC (Bio-STAMP) | withdrawn | Phase 2 | 0 | Masonic Cancer Center, University of MinnesotaOTHER | 0 | Feb 27, 2023 | clinicaltrials |
| NCT03982173 | Basket Trial for Combination Therapy With Durvalumab (Anti-PDL1) (MEDI4736) and Tremelimumab (Anti-CTLA4) in Patients With Metastatic Solid Tumors(MATILDA) | withdrawn | Phase 2 | 0 | Gustave Roussy, Cancer Campus, Grand ParisOTHER | 0 | Jan 26, 2023 | clinicaltrials |
| NCT03987568 | Characterize Tumor Hypoxia by Magnetic Resonance Imaging | withdrawn | N/A | 0 | Wake Forest University Health SciencesOTHER | 0 | Dec 21, 2022 | clinicaltrials |
| NCT04742972 | Prostate PMSABR Study | withdrawn | N/A | 0 | Darren PoonOTHER | 0 | Dec 9, 2022 | clinicaltrials |
| NCT00581503 | Early Detection and Staging of Endobronchial Lung and Pleural Cancer, Airway Injury, and Prostate Cancer | withdrawn | — | 0 | University of California, IrvineOTHER | 1 | Oct 20, 2022 | clinicaltrials |
| NCT03709550 | Enzalutamide and Decitabine in Treating Patients With Metastatic Castration Resistant Prostate Cancer | withdrawn | Phase 1 / Phase 2 | 0 | Roswell Park Cancer InstituteOTHER | 1 | Oct 5, 2022 | clinicaltrials |
| NCT02290366 | Prospective Evaluation of Focal Brachytherapy Using Cesium-131 For Patients With Low Risk Prostate Cancer | withdrawn | N/A | 0 | Ronald M. Benoit, MDOTHER | 1 | Aug 29, 2022 | clinicaltrials |
| NCT05191017 | Study of NUV-422 in Combination With Enzalutamide in Patients With mCRPC | withdrawn | Phase 1 / Phase 2 | 0 | Nuvation Bio Inc.INDUSTRY | 1 | Aug 5, 2022 | clinicaltrials |
| NCT04288336 | Daily, Long-Term Intermittent Fasting for the Prevention of PSA-Recurrence in Patients With Localized Prostate Cancer After Radical Prostatectomy | withdrawn | Early Phase 1 | 0 | Mayo ClinicOTHER | 1 | Jul 11, 2022 | clinicaltrials |
| NCT03823001 | Virtual Prostate Biopsy Protocol for Patients on Active Surveillance and at Risk of Prostate Cancer | withdrawn | N/A | 0 | Case Comprehensive Cancer CenterOTHER | 1 | May 20, 2022 | clinicaltrials |
| NCT04331717 | Bariatric Arterial Embolization for Men Starting Hormones for Prostate Cancer(BASH-PC) | withdrawn | Phase 2 | 0 | Sidney Kimmel Comprehensive Cancer Center at Johns HopkinsOTHER | 1 | May 2, 2022 | clinicaltrials |
| NCT04765423 | Fluciclovine (Axumin) PET/CT vs. NaF PET/CT in Prostate Cancer Osseous Metastatic Disease | withdrawn | N/A | 0 | Case Comprehensive Cancer CenterOTHER | 1 | Apr 1, 2022 | clinicaltrials |
| NCT00482157 | Calcitriol or Placebo in Men for Prostate Cancer Active Surveillance | withdrawn | N/A | 0 | Stanford UniversityOTHER | 0 | Mar 3, 2022 | clinicaltrials |
| NCT01826838 | Study of Dasatinib, Androgen Deprivation Therapy and Radiation(BrUOGPR255) | withdrawn | Phase 1 | 0 | Brown UniversityOTHER | 0 | Feb 24, 2022 | clinicaltrials |
| NCT04339920 | Spermine Measuring Device Evaluation Protocol | withdrawn | — | 0 | Chinese University of Hong KongOTHER | 1 | Jan 4, 2022 | clinicaltrials |
| NCT03800784 | Study of 18F-DCFPyL PET/CT Imaging in Patients With Prostate Cancer | withdrawn | Phase 2 / Phase 3 | 0 | Sidney Kimmel Comprehensive Cancer Center at Johns HopkinsOTHER | 1 | Dec 15, 2021 | clinicaltrials |
| NCT03495479 | Aneustat Treatment of Localized Prostate Cancer Under Active Surveillance(CAMPAS) | withdrawn | — | 0 | Omnitura Therapeutics, Inc.INDUSTRY | 0 | Oct 18, 2021 | clinicaltrials |
Data updated 22 days agoSource updated May 2, 2024source: clinicaltrials